WELCOME
  • Home
    • About the Haplo SCD Consortium
  • Patients & Families
    • Disease Information >
      • Signs and Symptoms
      • Treatment Options
    • Parent-To-Child (Haplo) Transplant >
      • Haplo Transplant Overview
      • Benefits of Haploidentical Donors
      • Meet a Donor
      • Meet a Patient
      • Trial Eligibility
      • Transplant Facilities Near You >
        • Travel and Housing
    • Video Education
    • Patient Advocacy Groups
    • Resources & External Links
  • Healthcare Professionals
    • Trial Aims and Hypotheses
    • Trial Eligibility
    • Preparative Regimen
    • Clinical Sites
    • Core Services
  • News & Events
  • Contact Us
Preparative Regimen

Patients will receive hydroxyurea and azathioprine starting day -59 to day -11, fludarabine on Days -15, -14, -13, -12, -11; busulfan twice daily on Days -10, -9, -8, -7; defibrotide beginning on day -10 and continuing through Day +21; thiotepa on day -6; cyclophosphamide on Days -5, -4; TLI on day -2; rabbit ATG on day -5,-4,-3, and -2. GVHD prophylaxis will consist of tacrolimus for 100 days post SCT and then tapered if ≤grade I AGVHD.

Picture
Reference: Freed J, Talano J, Small T, Ricci A, Cairo MS. Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. Bone Marrow Transplant. 2012;47(12):1489-1498.
Back to Trial Aims and Hypotheses
Haplo Sickle Cell Disease Consortium
Contact Us       About Us